Drug intelligence / Profile preview

artemin

Development stage
Phase 2
Modality
Recombinant Proteins and Enzymes
Administration
Subcutaneous, Intravenous, Intrathecal
01

Overview

Artemin is a neurotrophic factor belonging to the glial cell line-derived neurotrophic factor (GDNF) family ligands. It is a disulfide-linked homodimeric protein encoded by the ARTN gene in humans. Artemin primarily supports neuronal development, differentiation, survival, and regeneration by signaling through a receptor complex composed of RET proto-oncogene receptor tyrosine kinase and GDNF family receptor alpha 3 co-receptor. It also binds to neural cell adhesion molecule (NCAM), which is required for some of its biological effects such as neurite outgrowth and neuroprotection[1][5][8]. Artemin has been shown to promote regeneration of injured peripheral nerves and functional recovery after nerve injury[4]. In addition to its role in the nervous system, artemin has been implicated in oncogenicity and drug resistance in certain cancers via activation of pathways such as AKT[6]. Clinical trials have investigated artemin for conditions like sciatica/radicular syndrome/painful lumbar radiculopathy[3].

Brand names
Neublastin
Other names
arteminARTNenovin
02

Targets

NCAM1 (Neural cell adhesion molecule 1)GFRA3 (GDNF family receptor alpha-3)GFRA2 (GDNF family receptor alpha-2)GFRA1 (Glial cell line-derived neurotrophic factor family receptor alpha 1)

Beyond the preview

Go deeper on artemin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on artemin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call